Search Orphan Drug Designations and Approvals
-
| Generic Name: | N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl]-2-[(4-ethylpiperazin-1-yl)methyl]quinoline-6-carboxamide |
|---|---|
| Date Designated: | 08/16/2023 |
| Orphan Designation: | Treatment of cholangiocarcinoma |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Nuvectis Pharma, Inc. 1 Bridge Plaza N. Fort Lee, New Jersey 07024 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







